Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CVTX - CV Therapeutics, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: A.J. Mullen who wrote (108)	11/3/2003 12:26:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 411

Isn't that odd? The whole situation is very unusual. Normally the AC meeting would be before the FDA issued an approvable/non-approvable letter. But the company/FDA couldn't make the original AC date, and so if the FDA wanted to meet the PDUFA date their only real option was an approvable letter. It wouldn't have made sense to give either full approval or a non-approvable letter in the context of a forthcoming AC meeting. Peter